Patrick van Berkel
Chief Tech/Sci/R&D Officer chez ADC THERAPEUTICS SA
Fortune : 3 M $ au 31/03/2024
Profil
Patrick van Berkel is currently the Chief Scientific Officer at ADC Therapeutics SA. Prior to his current position, he worked at Genmab A as the VP-Antibody, Technology & Chemistry from 2003 to 2012.
Dr. van Berkel holds a doctorate degree from the University of Leiden, which he obtained in 1998.
He also has an undergraduate degree from Radboud University Nijmegen, which he received in 1991.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ADC THERAPEUTICS LTD
0,76% | 01/02/2023 | 623 467 ( 0,76% ) | 3 M $ | 31/03/2024 |
Postes actifs de Patrick van Berkel
| Sociétés | Poste | Début |
|---|---|---|
| ADC THERAPEUTICS SA | Chief Tech/Sci/R&D Officer | 01/08/2012 |
Anciens postes connus de Patrick van Berkel
| Sociétés | Poste | Fin |
|---|---|---|
| GENMAB A/S | Chief Tech/Sci/R&D Officer | 01/01/2012 |
Formation de Patrick van Berkel
| University of Leiden | Doctorate Degree |
| Radboud University Nijmegen | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GENMAB A/S | Health Technology |
| ADC THERAPEUTICS SA | Health Technology |
